ALLMedicine™ Prurigo Nodularis Center

Mar 22nd, 2023 - NEW ORLEANS – Nemolizumab monotherapy for 16 weeks improved itch, skin lesions, and sleep disturbances in adults with prurigo nodularis (PN), results from a phase 3 trial demonstrated. Nemolizumab is a first-in-class investigational monoclonal ant.

Mar 15th, 2023 - Effectiveness of Dupilumab in Pediatric Patient With Prurigo Nodularis-Like Atopic Dermatitis.|2023|Yiling Y,Ali K,Jiayang D,Qiu Y,Kai G,|

Mar 10th, 2023 - The study comprises of a 12 week double-blind, vehicle-controlled (DBVC) treatment period, followed by a 40 week open label extension period, and 30 day safety follow-up period During the double blind period, all PN-affected areas identified at ba...

Mar 6th, 2023 - The study comprises of a 12 week double-blind, vehicle-controlled (DBVC) treatment period, followed by a 40 week open label extension period, and 30 day safety follow-up period During the double blind period, all PN-affected areas identified at ba...

Feb 28th, 2023 - Failure of Dupilimab With Severe Prurigo Nodularis That Responded Well to Abrocitinib.|2023|Vander Does A,Yosipovitch G,|

Mar 10th, 2023 - The study comprises of a 12 week double-blind, vehicle-controlled (DBVC) treatment period, followed by a 40 week open label extension period, and 30 day safety follow-up period During the double blind period, all PN-affected areas identified at ba...

Mar 6th, 2023 - The study comprises of a 12 week double-blind, vehicle-controlled (DBVC) treatment period, followed by a 40 week open label extension period, and 30 day safety follow-up period During the double blind period, all PN-affected areas identified at ba...

Feb 27th, 2023 - Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Around one-third of patients with AD have had at least 1 incidence of prurigo nodularis (PN), which is characterized by intense, persiste...

Feb 8th, 2023 - This is a Phase 2a/b randomized, double-blind, placebo-controlled study to investigate the efficacy, safety, tolerability, PK and immunogenicity of Vixarelimab administered subcutaneously (SC) in subjects with prurigo nodularis experiencing prurit...

Feb 8th, 2023 - Chronic Prurigo (CPG) is a skin disease of unknown incidence and prevalence that can occur in all age groups including children, but which is most prevalent in elderly people. CPG was defined as a distinct disease in 2018 by the Task Force Pruritu...

Mar 22nd, 2023 - NEW ORLEANS – Nemolizumab monotherapy for 16 weeks improved itch, skin lesions, and sleep disturbances in adults with prurigo nodularis (PN), results from a phase 3 trial demonstrated. Nemolizumab is a first-in-class investigational monoclonal ant.

Feb 5th, 2023 - Atopic dermatitis (AD) is one of the most common chronic, inflammatory skin diseases encountered by dermatologists. AD is characterized by pruritus and a chronic course of exacerbations and remissions.

Sep 29th, 2022 - The FDA has approved dupilumab (Dupixent) as the first treatment with an indication for prurigo nodularis, Sanofi and Regeneron announced. A chronic inflammatory skin condition affecting about 75,000 Americans, prurigo nodularis causes persistent ...

Sep 29th, 2022 - The Food and Drug Administration has approved dupilumab for treating adults with prurigo nodularis, the first treatment approved for this indication, according to a press release from the manufacturers. Recent studies of dupilumab (Dupixent), whic...

Sep 9th, 2022 - Patients with prurigo nodularis (PN) who had severe itch and high lesion counts and whose condition was inadequately controlled with prior therapies experienced significant improvements with dupilumab (Dupixent), indicate results from the phase 2 ...